Results 11 to 20 of about 21,372 (208)

Venetoclax triggers sublethal apoptotic signaling in venetoclax-resistant acute myeloid leukemia cells and induces vulnerability to PARP inhibition and azacitidine

Cell Death and Disease
Venetoclax plus azacitidine treatment is clinically beneficial for elderly and unfit acute myeloid leukemia (AML) patients. However, the treatment is rarely curative, and relapse due to resistant disease eventually emerges.
Mahesh Tambe, Sarah Unterberger, Mette C. Kriegbaum, Ida Vänttinen, Ezgi June Olgac, Markus Vähä-Koskela, Mika Kontro, Krister Wennerberg, Caroline A. Heckman   +8 more
doaj   +2 more sources

Ex vivo venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia

Haematologica, 2022
The BCL-2 inhibitor venetoclax has revolutionized the treatment of acute myeloid leukemia (AML) in patients not benefiting from intensive chemotherapy. Nevertheless, treatment failure remains a challenge, and predictive markers are needed, particularly ...
Heikki Kuusanmäki, Sari Kytölä, Ida Vänttinen, Tanja Ruokoranta, Amanda Ranta, Jani Huuhtanen, Minna Suvela, Alun Parsons, Annasofia Holopainen, Anu Partanen, Milla E.L. Kuusisto, Sirpa Koskela, Riikka Räty, Maija Itälä-Remes, Imre Västrik, Olli Dufva, Sanna Siitonen, Kimmo Porkka, Krister Wennerberg, Caroline A. Heckman, Pia Ettala, Marja Pyörälä, Johanna Rimpiläinen, Timo Siitonen, Mika Kontro   +24 more
doaj   +2 more sources

Cancer‐Associated BCL‐2 Mutants Reveal Mechanisms Towards Venetoclax Resistance

Advanced Science, EarlyView.
Venetoclax (VEN) resistance in chronic lymphocytic leukemia arises from diverse BCL2 mutations. We map mechanisms contributing to VEN resistance across common BCL‐2 variants. G101V and D103Y reduce drug binding and increase sequestration of pro‐apoptotic proteins. V156D blocks VEN allosterically.
Jonas Aufdermauer, Ian de Ridder, Mahjoobeh Ehsani, Marasim Khan, Justin Kale, Lukas P. Frenzel, David Andrews, Spyridoula Karamanou, Ana J. Garcia‐Saez, Geert Bultynck   +9 more
wiley   +2 more sources

Paired comparisons of venetoclax concentration in cerebrospinal fluid, bone marrow, and plasma in acute leukemia patients

Clinical and Translational Science
Venetoclax, a small molecule inhibitor of BCL‐2, has demonstrated efficacy in treating acute leukemias and has been recommended as one of the first‐line anti‐leukemia therapies.
Yuan Jian, Feifei Han, Ying Zhu, Chuanying Geng, Yanru Zhang, Yin Wu, Yun Leng, Wenming Chen, Zhuoling An, Hong‐Hu Zhu   +9 more
doaj   +2 more sources

First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia [PDF]

, 2023
BACKGROUNDRandomized trials of venetoclax plus anti-CD20 antibodies as first-line treatment in fit patients (i.e., those with a low burden of coexisting conditions) with advanced chronic lymphocytic leukemia (CLL) have been lacking.METHODSIn a phase 3 ...
Holger Hebart, Niemann, Carsten U.,, Monika Brüggemann, Ilse Christiansen, Thomas Illmer, Arnon P. Kater, Baumann, Michael, Gaska, Tobias, De Silva, Nisha, Koene, Harry, Josien C. Regelink, Fürstenau, Moritz, Schoettker, Bjoern,, Tausch, Eugen, Geisler, Christian, Mark-David Levin, Kirsten Fischer, Regelink, Josien C.,, Maria B.L. Leys, Wendtner, Clemens Martin, Janssens, Ann, Simon, Florian, Schneider, Christof,, Ulrich Jäger, Eichhorst, Barbara,, Gaska, Tobias,, Gregor, Michael, Nösslinger, Thomas, von Tresckow, Julia,, da Cunha-Bang, Caspar, Lotfi, Kourosh,, Clemens-Martin Wendtner, Frederiksen, Henrik,, Goede, Jereon,, Christof Schneider, Florian Simon, Thornton, Patrick, Leys, Maria B.L., Jaeger, Ulrich,, Illmer, Thomas,, Mels Hoogendoorn, Levin, Mark David, Zhang, Can,, Poulsen, Christian B.,, Schöttker, Björn, Juliusson, Gunnar, Noesslinger, Thomas,, Illmer, Thomas, Fischer, Kirsten, Niemann, Carsten U., De Silva, Nisha,, Janssens, Ann,, Staber, Philipp B., Caspar da Cunha-Bang, Juliusson, Gunnar,, Widmer, Anouk,, Geisler, Christian,, Björn Schöttker, Fischer, Kirsten,, Eugen Tausch, Fink, Anna-Maria,, Barbara Eichhorst, Ritgen, Matthias,, Marjolein van der Klift, Stephan Stilgenbauer, Jereon Goede, Gregor, Michael,, von Tresckow, Julia, Hebart, Holger,, Kourosh Lotfi, Vesa Lindström, Zhang, Can, Frederiksen, Henrik, Carsten U. Niemann, Baumann, Michael,, Stilgenbauer, Stephan,, Levin, Mark-David, Sandra Robrecht, Schneider, Christof, Gunnar Juliusson, Levin, Mark-David,, Ann Janssens, Robrecht, Sandra, Hoogendoorn, Mels, Leys, Maria B L, Bahlo, Jasmin, Wendtner, Clemens-Martin, Tamar Tadmor, da Cunha-Bang, Caspar,, Leys, Maria B. L., Henrik Frederiksen, Fink, Anna-Maria, Michael Gregor, Poulsen, Christian B., Tobias Gaska, Niemann, Carsten U, Tadmor, Tamar,, Regelink, Josien C., Frederiksen, Henrik; id_orcid, Christiansen, Ilse,, Marinus van Oers, Nisha De Silva, Harry Koene, Julia von Tresckow, Poulsen, Christian B, Regelink, Josien C, Wendtner, Clemens-Martin,, Bahlo, Jasmin,, Hallek, Michael,, Karl A. Kreuzer, Fuerstenau, Moritz,, Brüggemann, Monika, van Oers, Marinus, van der Klift, Marjolein, Tadmor, Tamar, Can Zhang, Jasmin Bahlo, Lindström, Vesa, Christian Geisler, Kater, Arnon P, Hoogendoorn, Mels,, Kater, Arnon P., van der Klift, Marjolein,, Leys, Maria B. L.,, Widmer, Anouk, Christian B. Poulsen, Stilgenbauer, Stephan, Michael Baumann, Lotfi, Kourosh, van Oers, Marinus,, Brueggemann, Monika,, Kater, Arnon P.,, Lindstrom, Vesa,, Tausch, Eugen,, Christiansen, Ilse, Simon, Florian,, Robrecht, Sandra,, Philipp B. Staber, Staber, Philipp B, Anouk Widmer, Enggaard, Lisbeth,, Anna-Maria Fink, Lisbeth Enggaard, Kreuzer, Karl A.,, Thornton, Patrick,, Hallek, Michael, Fink, Anna Maria, Koene, Harry,, Thomas Nösslinger, Goede, Jereon, Kreuzer, Karl A, Staber, Philipp B.,, Enggaard, Lisbeth, Patrick Thornton, Michael Hallek, Hebart, Holger, Matthias Ritgen, Moritz Fürstenau, Eichhorst, Barbara, Kreuzer, Karl A., Jäger, Ulrich, Ritgen, Matthias   +161 more
core   +3 more sources

Chronic lymphocytic leukemia following venetoclax treatment failure [PDF]

, 2022
Venetoclax (ABT-199) is a highly selective and potent inhibitor of BCL-2, capable of inducing deep remission in chronic lymphocytic leukemia (CLL). The introduction of this compound to the treatment armamentarium of CLL represented a real breakthrough ...
Puła, Bartosz; Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland, Sośnia, Oktawia; Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland   +1 more
core   +2 more sources

Electrolyte disorders secondary to venetoclax [PDF]

, 2021
Emerging cancer drugs introduce new forms of nephrotoxicity that may also present as electrolyte disorders. Here, we report a patient with non-Hodgkin lymphoma who developed severe hypokalaemia with concurrent hypophosphataemia, hypocalcaemia and ...
Hoorn, Ewout J.; id_orcid, Hoorn, Ewout J., van der Lubbe, Nils, Lugtenburg, Pieternella J.   +3 more
core   +2 more sources

Rationale for Combining the BCL2 Inhibitor Venetoclax with the PI3K Inhibitor Bimiralisib in the Treatment of IDH2- and FLT3-Mutated Acute Myeloid Leukemia [PDF]

, 2022
In October 2020, the FDA granted regular approval to venetoclax (ABT-199) in combination with hypomethylating agents for newly-diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or in patients with comorbidities precluding intensive ...
Mandhair, Harpreet, Pabst, Thomas, Harpreet Mandhair, Katja Seipel, Yvo Brügger, Thomas Pabst, Seipel, Katja, Bacher, Ulrike, Ulrike Bacher, Brügger, Yvo   +9 more
core   +2 more sources

Nucleolin Alterations and ROS Production Associate With Sensitivity of AML Cells to Venetoclax. [PDF]

FASEB J
Venetoclax‐induced Bcl‐2 inhibition corresponds with Mcl‐1 attenuation and decrease of Nucleolin (NCL) level and activity in sensitive cells. Simultaneously, distinct cell subpopulations with opposite mitochondrial (CellROX label, magenta) and cellular (H2DCFDA stain, green) ROS occur, and the H2DCFDA‐positive population shows markers of early ...
Wolfová K, Otevřelová P, Brodská B.
europepmc   +2 more sources

Outcomes following venetoclax-based treatment in therapy-related myeloid neoplasms [PDF]

, 2022
Therapy-related myeloid neoplasms (t-MN) are aggressive malignancies in need of effective therapies. The BCL-2 inhibitor venetoclax represents a paradigm shift in the treatment of acute myeloid leukemia.
Shah, MV, He, R, Wei, AH, Tiong, IS, Chhetri, R, Al-Kali, A, Alkhateeb, HB, Kok, CH, Begna, KH, Baranwal, A, Hiwase, D, Dholakia, R, Patnaik, MM, Gangat, N, Greipp, PT   +14 more
core   +2 more sources